Literature DB >> 27184223

Resistant in-stent restenosis in the drug eluting stent era.

Kleanthis Theodoropoulos1, Marco G Mennuni1,2, George D Dangas1, Omar A Meelu1, Sameer Bansilal1, Usman Baber1, Samantha Sartori1, Jason C Kovacic1, Pedro R Moreno1, Samin K Sharma1, Roxana Mehran1, Annapoorna S Kini1.   

Abstract

BACKGROUND: In the drug eluting stent (DES) era, repeat in-stent restenosis (ISR) of the same coronary lesion, despite percutaneous coronary intervention (PCI), is a rare but challenging problem that has not been reported. We aim to describe what we propose as the occurrence of "resistant"-ISR (R-ISR) in the DES era, including angiographic patterns and outcomes.
METHODS: We defined R-ISR as the recurrence of an ISR episode after successful treatment of the same lesion. We identified 276 consecutive patients with 291 lesions who had R-ISR between May 2003 and June 2012. Quantitative coronary angiography (QCA) was performed for the first and second ISR episodes. Outcomes at one year, including death, myocardial infarction (MI), and target lesion failure (TLF), were analyzed.
RESULTS: Patients with R-ISR had a high frequency of diabetes (62%), chronic kidney disease (39%), bifurcation lesions (51%), and moderate to severe calcified lesions (52%). The most common pattern of R-ISR was focal (77%). R-ISR lesions were treated with DES implantation (55%) or balloon-only strategy (45%). The mortality rate and TLF at 2-years were 9.3% and 51% respectively. The overall 2-year TLF rate did not vary with the originally implanted stent, angiographic pattern (focal versus diffuse), or revascularization strategy.
CONCLUSIONS: R-ISR appears to consist predominantly of focal lesions and occurs in patients at high clinical and angiographic risk, conceivably owing to their unique diabetic and coronary calcification profile. Clinical outcomes are suboptimal irrespective of angiographic pattern or treatment strategy, indicating the recalcitrant nature of the disease, and need for aggressive treatment of cardiovascular risk factors and novel interventional approaches.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  coronary artery disease; drug eluting stent; restenosis

Mesh:

Year:  2016        PMID: 27184223     DOI: 10.1002/ccd.26559

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  6 in total

1.  Optimizing endothelial cell functionalization for cell therapy of vascular proliferative disease using a direct contact co-culture system.

Authors:  Mark R Battig; Ilia Fishbein; Robert J Levy; Ivan S Alferiev; David Guerrero; Michael Chorny
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

2.  Cardiovascular delivery of drugs and biotherapeutics.

Authors:  Michael Chorny; Robert J Levy; Gershon Golomb
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

Review 3.  Comparison of drug-eluting balloon versus drug-eluting stent for treatment of coronary artery disease: a meta-analysis of randomized controlled trials.

Authors:  Lulu Liu; Bin Liu; Jiajun Ren; Gang Hui; Chao Qi; Junnan Wang
Journal:  BMC Cardiovasc Disord       Date:  2018-03-02       Impact factor: 2.298

4.  The clinical features and prognosis of type 4C myocardial infarction in patients with non-ST-segment elevation myocardial infarction.

Authors:  Jixiang Wang; Honggang Gao; Jianyong Xiao; Mingdong Gao; Yin Liu; Jing Gao
Journal:  Ann Transl Med       Date:  2021-07

5.  Three contemporary thin-strut drug-eluting stents implanted in severely calcified coronary lesions of participants in a randomized all-comers trial.

Authors:  Rosaly A Buiten; Eline H Ploumen; Paolo Zocca; Carine J M Doggen; K Gert van Houwelingen; Peter W Danse; Carl E Schotborgh; Martin G Stoel; Martijn Scholte; Gerard C M Linssen; Frits H A F de Man; Clemens von Birgelen
Journal:  Catheter Cardiovasc Interv       Date:  2020-04-01       Impact factor: 2.692

6.  Rapamycin and Paclitaxel Affect Human Aortic Smooth Muscle Cells-Derived Foam Cells Viability and Proliferation.

Authors:  Yongbo Kang; Yue Cai; Wei Pan
Journal:  Braz J Cardiovasc Surg       Date:  2022-05-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.